2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.
Multi-Organ Transplant Program, University of Toronto, Toronto, ON, Canada.
IntroductionLiving donor liver transplantation (LDLT) can reduce waiting times and potentially decrease drop-out rates for cirrhotic patients with HCC. However, it has also been reported…2016 American Transplant Congress
Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?
Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…2016 American Transplant Congress
Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.
Transplantation, Toronto General Hospital, Toronto, ON, Canada.
Introduction: We compared the impact of estimating graft to recipient body weight ratio (GBWR) with actual body weight (ABW) and ideal body weight (IBW) on…2016 American Transplant Congress
Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.
Background: Medication non-adherence (MNA) is a significant contributor to late graft loss in kidney transplant recipients. The aim of this study was to develop and…2016 American Transplant Congress
Impact of Allograft Dysfunction and Early Low Grade Proteinuria on Survival in Expanded Criteria Donor Kidney Transplant Recipients.
Nephrology, Hospital Regional de Málaga, Málaga, Spain.
Introduction. Recent studies have demonstrated a relationship between low-grade proteinuria and worse graft survival, but this has not been fully studied in expanded criteria donor…2016 American Transplant Congress
Can We Predict New-Onset Diabetes After Transplantation Previously?
Objectives: New-onset diabetes after transplantation (NODAT), one of the important complications after kidneytransplantation, leads to reduce graft survival rate and increase patient morbidity and mortality.…2016 American Transplant Congress
Identification of Biomarkers for Progressive Fibrosis in Renal Transplant Patients Using Novel Chemical Imaging Approaches.
BackgroundThe main treatment for end-stage renal disease is kidney transplantation, however close monitoring of post-transplant biopsies is required to identify subclinical complications. In this study,…2016 American Transplant Congress
Myeloid-Derived Suppressor Cells (MDSC) Accumulate in Intestinal Transplant (IT) Patients.
[Background] IT is an efficacious treatment for chronic intestinal failure. Recent advance of immunosuppressive regimens have decreased the rejection rate and improved patient survival. The…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 180
- Next Page »